menu
    • menu

    Company profile for OrthoTrophix

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    OrthoTrophix is focused on the development and commercialization of revolutionary therapies that offer new solutions to the unmet medical needs of patients suffering from diseases and conditions involving hard tissues. OrthoTrophix believes that its product candidates have distinct advantages over existing therapies. The Company’s most advanced project is TPX-100, a candidate first-in-class disease modifying osteoarthriti...
    OrthoTrophix is focused on the development and commercialization of revolutionary therapies that offer new solutions to the unmet medical needs of patients suffering from diseases and conditions involving hard tissues. OrthoTrophix believes that its product candidates have distinct advantages over existing therapies. The Company’s most advanced project is TPX-100, a candidate first-in-class disease modifying osteoarthritis drug (DMOAD). OrthoTrophix has successfully demonstrated safety and clinical efficacy of TPX-100 in a Phase 2 placebo-controlled study in subjects with knee osteoarthritis in fifteen centers across the U.S.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OrthoTrophixUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    303 Hegenberger Rd., Suite 312 Oakland, CA 94621
    Telephone
    Telephone
    510-488-3832
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.orthotrophix.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    OrthoTrophix Completes Phase 2B Enrollment Early For TPX-100
    OrthoTrophix Completes Phase 2B Enrollment Early For TPX-100

    24 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/orthotrophix-announces-early-completion-of-enrollment-in-phase-2b-trial-of-tpx-100-in-knee-osteoarthritis-302695405.html

    PR NEWSWIRE
    24 Feb 2026
    Share Share
    OrthoTrophix Starts Ph2b Trial of TPX-100 in Knee Osteoarthritis
    OrthoTrophix Starts Ph2b Trial of TPX-100 in Knee Osteoarthritis

    12 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/orthotrophix-initiated-phase-2b-clinical-trial-of-tpx-100-in-patients-with-mild-to-severe-knee-osteoarthritis-302451562.html

    PR NEWSWIRE
    12 May 2025
    Share Share
    TPX-100: OrthoTrophix Presents the Latest Clinical Data at BIO 2022
    TPX-100: OrthoTrophix Presents the Latest Clinical Data at BIO 2022

    01 Jun 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/tpx-100-orthotrophix-presents-the-latest-clinical-data-at-bio-2022-301557983.html

    PRNEWSWIRE
    01 Jun 2022
    Share Share
    OrthoTrophix Presents Data on Joint Bone Shape as a Possible Surrogate Marker
    OrthoTrophix Presents Data on Joint Bone Shape as a Possible Surrogate Marker

    08 Apr 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/tpx-100-orthotrophix-presents-new-data-suggesting-joint-bone-shape-as-a-possible-surrogate-marker-for-virtual-joint-replacement-in-knee-osteoarthritis-301517118.html

    PRNEWSWIRE
    08 Apr 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search